Hematology/Oncology

Top Story

Universal BRCA testing might not be worth the cost

September 4, 2015

Universal BRCA1/2 testing may not be cost-effective due to the rarity of these mutations and cost of testing, according to a viewpoint published in JAMA Oncology.

“The cost of BRCA testing would need to drop by 90 percent to be cost-effective for the whole population,” Patricia A. Ganz, MD, director of the division of cancer prevention and control research at UCLA Jonsson Comprehensive Cancer Center, said in a press release.

In the Journals

Eliminating pretreatment biopsy reduced cost without compromising care for BCC

September 4, 2015
A simplified detect-and-treat scheme that eliminates the biopsy before initiating treatment of basal cell carcinoma resulted in cost savings while maintaining quality of…
In the Journals

Immune perturbations may increase melanoma risk among certain non-Hodgkin's lymphoma survivors

September 4, 2015
Certain chemotherapeutic agents and immune-related medical conditions appeared to contribute to increased melanoma risk among older survivors of a specific…
FDA News

FDA grants breakthrough therapy designation to ACE910 for hemophilia A

September 4, 2015
The FDA granted breakthrough therapy designation to ACE910 for the prophylactic treatment of patients aged at least 12 years who have hemophilia A with factor VIII…
In the JournalsPerspective

Advanced care planning rates increase modestly among patients with cancer

September 4, 2015
The use of advanced care planning among patients with cancer increased modestly between 2000 and 2012, according to an analysis of prospectively collected survey data.A…
More News Headlines »
CME
Hematology Oncology Case Consults

The Patient with Multiple Myeloma

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with multiple myeloma.
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
Tailored Therapies for Myelodysplastic Syndromes

Tailored Therapies for Myelodysplastic Syndromes

This activity is supported by an educational grant from Celgene Corporation.

Myelodysplastic syndromes (MDS) represent a group of myeloid clonal hemopathies with heterogeneous clinical…
More »
morganatic-roan
morganatic-roan